Tumor-host cell interactions in the bone disease of myeloma : Skeletal Complications of CancerFOWLER, Jessica A; EDWARDS, Claire M; CROUCHER, Peter I et al.Bone (New York, NY). 2011, Vol 48, Num 1, pp 121-128, issn 8756-3282, 8 p.Article

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancerEATON, Colby L; WELLS, Jason M; HOLEN, Ingunn et al.The Prostate. 2004, Vol 59, Num 3, pp 304-310, issn 0270-4137, 7 p.Article

Bisphosphonates in preclinical bone oncologyCLEZARDIN, Philippe; BENZAÏD, Ismahène; CROUCHER, Peter I et al.Bone (New York, NY). 2011, Vol 49, Num 1, pp 66-70, issn 8756-3282, 5 p.Article

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cellsHOLEN, Ingunn; CROUCHER, Peter I; HAMDY, Freddie C et al.Cancer research (Baltimore). 2002, Vol 62, Num 6, pp 1619-1623, issn 0008-5472Article

Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790HAID, Andreas; HANSEN, Rikke R; THOMSEN, Mette W et al.International journal of cancer (Print). 2009, Vol 125, Num 5, pp 1177-1185, issn 0020-7136, 9 p.Article

Inhibiting Dickkopf-1 (Dkkl) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple MyelomaHEATH, Deborah J; CHANTRY, Andrew D; BUCKLE, Clive H et al.Journal of bone and mineral research (Print). 2009, Vol 24, Num 3, pp 425-436, issn 0884-0431, 12 p.Article

Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myelomaVANDERKERKEN, Karin; MEDICHERLA, Satya; CROUCHER, Peter I et al.Cancer research (Baltimore). 2007, Vol 67, Num 10, pp 4572-4577, issn 0008-5472, 6 p.Article

Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo : a role in tumour cell survival?HOLEN, Ingunn; CROSS, Simon S; NEVILLE-WEBBE, Helen L et al.Breast cancer research and treatment. 2005, Vol 92, Num 3, pp 207-215, issn 0167-6806, 9 p.Article

Significant Deterioration in Nanomechanical Quality Occurs Through Incomplete Extrafibrillar Mineralization in Rachitic Bone: Evidence From In-Situ Synchrotron X-Ray Scattering and Backscattered Electron ImagingKARUNARATNE, Angelo; ESAPA, Christopher R; BROWN, Steve Dm et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 4, pp 876-890, issn 0884-0431, 15 p.Article

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myelomaHEATH, Deborah J; VANDERKERKEN, Karin; XIN CHENG et al.Cancer research (Baltimore). 2007, Vol 67, Num 1, pp 202-208, issn 0008-5472, 7 p.Article

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myelomaTERPOS, Evangelos; HEATH, Deborah J; DIMOPOULOS, Meletios-Athanassios et al.British journal of haematology. 2006, Vol 135, Num 5, pp 688-692, issn 0007-1048, 5 p.Article

Bisphosphonates: Mechanisms of action in multiple myelomaSHIPMAN, Claire M; ROGERS, Michael J; VANDERKERKEN, Karin et al.Acta oncologica (Stockholm). 2000, Vol 39, Num 7, pp 829-835, issn 0284-186XConference Paper

Apomine™, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivoEDWARDS, Claire M; MUELLER, Gabrielle; VANDERKERKEN, Karin et al.International journal of cancer. 2007, Vol 120, Num 8, pp 1657-1663, issn 0020-7136, 7 p.Article

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantationPOLITOU, Marianna C; HEATH, Deborah J; RAHEMTULLA, Amin et al.International journal of cancer. 2006, Vol 119, Num 7, pp 1728-1731, issn 0020-7136, 4 p.Article

Multifunctional role of matrix metalloproteinases in multiple myeloma: A study in the 5T2MM mouse modelVAN VALCKENBORGH, Els; CROUCHER, Peter I; VAN RIET, Ivan et al.The American journal of pathology. 2004, Vol 165, Num 3, pp 869-878, issn 0002-9440, 10 p.Article

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survivalCROUCHER, Peter I; DE RAEVE, Hendrik; PERRY, Mark J et al.Journal of bone and mineral research (Print). 2003, Vol 18, Num 3, pp 482-492, issn 0884-0431, 11 p.Article

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myelomaCROUCHER, Peter I; SHIPMAN, Claire M; DUNSTAN, Colin R et al.Blood. 2001, Vol 98, Num 13, pp 3534-3540, issn 0006-4971Article